Ginkgo Bioworks Reports Q3 2026 Results with Improved Net Loss and Reduced Cash Burn
Ginkgo Bioworks (DNA) reported third-quarter 2026 financial results characterized by a strategic shift toward autonomous laboratory platforms. While quarterly revenue declined 6% year-over-year to $28 million, the company showed significant progress in cost management. Net loss from continuing operations improved by 44% compared to the prior year, and Adjusted EBITDA saw a substantial 58% improvement, reaching negative $22 million. The company is actively executing restructuring efforts, resulting in a 48% decrease in R&D expenses and a 32% reduction in G&A expenses. Despite facing $14 million in excess lease costs for unused space, Ginkgo successfully signed 22 new Cloud Lab customers during the quarter. Management reaffirmed its full-year 2026 cash burn guidance of $125 million to $150 million as they continue transitioning biopharma customers toward their automation services.
Tickers: $DNA
Topics: Adjusted EBITDA Cash Flow Net Loss R&D Expense Revenue
Read the full article at Motley Fool
Part of the story Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026 (11 articles)